U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244835) titled 'A Study of DEG6498 in Participants With Solid Tumors' on Nov. 13.
Brief Summary: The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are:
* what is an appropriate dose to be given to participants?
* are the side effects of treatment manageable?
Participants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicia...